2 Wall Street Analysts Think Argenx Can Soar More Than 40%. Here's Why They're Right.

Key Points Wells Fargo and UBS have 12-month price targets for Argenx that are more than 40% above the current share price. Argenx's momentum and clinical successes appear to justify these lofty expectations. 10 stocks we like better than Argenx Se › Argenx (NASDAQ: ARGX) has been a solid winner for investors over the last 12 months, with its shares rising by roughly 30%. Wall Street thinks that the biotech stock can go even higher. The consensus one-year price target for Argenx reflects a potential upside of around 20%. Two analysts, though, are even more bullish. Wells Fargo 's (NYSE: WFC) Derek Archila and UBS ' (NYSE: UBS) Xian Deng predict that Argenx's share price can soar more than 40% over the next 12 months.